FOLD
NASDAQ HealthcareAmicus Therapeutics, Inc. - Common Stock
Biotechnology
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
�� 市场数据
| 价格 | $14.46 |
|---|---|
| 成交量 | 2,159,569 |
| 市值 | 4.54B |
| 贝塔系数 | 0.480 |
| RSI（14日） | 66.7 |
| 200日均线 | $10.63 |
| 50日均线 | $14.38 |
| 52周最高 | $14.48 |
| 52周最低 | $5.51 |
| Forward P/E | 17.66 |
| Price / Book | 16.39 |
🎯 投资策略评分
FOLD 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (58/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (25/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 FOLD in your text
粘贴任何文章、记录或帖子 — 工具将提取 FOLD 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.